All In Biotech

Drug Trial Radar · NCT02877264

A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

A Randomized, Single-Center, Open-Label, Three-Period, Six-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Product Formulations in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jun 2016

Primary completion

Aug 2016

Sponsor

Lead sponsor
Aviragen TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Who can join
All sexes, from 19 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, single-center, open-label, three-period, six-sequence, crossover, comparative study to evaluate the oral bioavailability of single doses of three vapendavir drug product formulations (the 264 mg free base tablet \[test drug\], 264 mg free base oral suspension \[test drug\], and two 132 mg phosphate salt capsules \[reference drug\]) in healthy volunteers. The study design consists of six dosing sequences. Each sequence comprises 3 periods and each subject is administered one of the three dosing formulations in the first period. A subject receives a different formulation in each of the subsequent periods, so that all subjects receive each formulation. The periods are separated by an approximate 7-day washout.

Conditions

  • Healthy

Interventions

  • vapendavir 132 mg capsuleDrug

  • vapendavir 264 mg tabletDrug

  • vapendavir 24 mg/mL oral suspensionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative oral bioavailability, as applicableTime frame: Study Day 0 - 17
  2. Maximum observed plasma concentration (Cmax)Time frame: Study Day 0 - 17
  3. Time at which Cmac was observed (Tmax)Time frame: Study Day 0 - 17
  4. Area under the plasma concentration time curve from time ) to the last measureable plasma concentration (AUC 0-last)Time frame: Study Day 0 - 17

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aviragen Investigational Site

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.